CombiGene establishes collaboration with Danish company Zyneyro to revolutionize the treatment of chronic pain

Chronic pain is a global scourge that causes enormous human suffering and astronomical costs to society. The need for new treatments is dramatic.

CombiGene and Zyneyro aim to develop a completely new and revolutionary way to treat pain based on modulation of neuronal signal transmission.

Latest news

New issue of Ingeneious!

Read more

CombiGene enters into collaboration agreement with Zyneyro for the development of a unique concept for effective relief of chronic pain

Read more

Stock information

Financial reports

Interim report January – September 2022 for CombiGene AB (publ)

Read more

Interim report January – June 2022 for CombiGene AB (publ)

Read more

CombiGene – the leading Nordic gene therapy company

CombiGene is currently conducting two gene therapeutic development projects: one for treatment of epilepsy that cannot otherwise be treated with drugs and one for treatment of lipodystrophy, a rare condition characterized by an abnormal distribution of fatty tissue in the body. 

CombiGene now has a well-established international network within both the pharmaceutical industry and academia. The ambition is to form strategic partnerships for continued development and commercialization of the two projects which CombiGene is currently pursuing and to identify potential new projects in areas in which it may be possible to apply gene therapy.

The epilepsy project – CG01

The focus is on developing a treatment method for epilepsy patients who cannot be helped by currently available therapies​

In order to prepare CG01 to meet the needs of a global submission the remaining preclinical program will be expanded and, in some parts, complemented with additional studies in collaboration with Spark

The lipodystrophy project – CGT2

The CGT2 project aims to develop a gene therapy treatment for partial lipodystrophy, a rare disease for which effective treatments are currently lacking

CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282

CombiGene´s project CGT2 is supported by the Eurostars Programme. Project ID: 114714

Academic collaborations

Within the framework of the epilepsy project CG01, CombiGene has been collaborating with Lund University and the University of Copenhagen for many years. In recent years, CombiGene has also established collaboration regarding the preclinical development of the lipodystrophy project CGT2 with Stockholm University, University Medical Center Hamburg-Eppendorf and University of Michigan Medical School.